Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Clin Pharmacokinet. 2017 Aug;56(8):941–951. doi: 10.1007/s40262-016-0486-0

Table 3.

Individual post-hoc pharmacokinetic parameter estimates derived using the final model.

Parameter 3 months – <3 years (N=54) 3 – <13 years (N=69) ≥13 years (N=22) Total (N=145)
CL (L/h) 0.60 (0.24–1.96) 1.23 (0.31–8.44) 2.56 (0.48–6.67) 1.02 (0.24–8.44)
CL_WT (L/h/kg) 0.058 (0.022–0.169) 0.058 (0.012–0.173) 0.049 (0.006–0.095) 0.056 (0.006–0.173)
Vss (L) 10.37 (4.88–19.33) 19.84 (6.37–156.74) 55.64 (20.41–111.0) 17.61 (4.88–156.74)
Vss_WT (L/kg) 1.40 (0.62–2.30) 1.40 (0.43–4.98) 1.25 (0.35–1.79) 1.40 (0.35–4.98)
Alpha half-life (h) 0.26 (0.13–0.39) 0.29 (0.11–0.65) 0.34 (0.11–0.50) 0.28 (0.11–0.65)
Beta half-life (h) 17.56 (8.57–25.41) 16.51 (8.19–39.19) 20.08 (12.02–53.57) 17.36 (8.19–53.57)

All data are presented as median (range). CL: clearance; CL_WT: weight-adjusted clearance; Vss: steady-state volume of distribution; Vss_WT: weight-adjusted steady-state volume of distribution.